Erudio Healtherudio.com
Drug
Trastuzumab deruxtecan trials: what clinicians said in public
No HCP commentary report on a trial studying trastuzumab deruxtecan yet. Erudio has found public clinician commentary on 38 clinical trials studying trastuzumab deruxtecan, including DESTINY-Breast04, DESTINY-Breast05, DESTINY-Breast06 and DESTINY-Breast11. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| DESTINY-Breast04 NCT03734029 · Daiichi Sankyo DeepView → | HER2-low unresectable or metastatic breast cancer | Phase 3 | Deep | View | |||
| DESTINY-Breast06 NCT04494425 · AstraZeneca DeepView → | hormone receptor-positive HER2-low or HER2-ultralow metastatic breast cancer | Phase 3 | Deep | View | |||
| DESTINY-Breast11 NCT05113251 · AstraZeneca DeepView → | high-risk HER2-positive early-stage breast cancer | Phase 3 | Deep | View | |||
| DESTINY-Breast05 NCT04622319 · Daiichi Sankyo DeepView → | HER2-positive residual invasive breast cancer following neoadjuvant therapy | Phase 3 | Deep | View | |||
| DESTINY-Breast09 NCT04784715 · AstraZeneca DeepView → | first-line HER2-positive metastatic breast cancer | Phase 3 | Deep | View | |||
| DESTINY-Breast03 NCT03529110 · Daiichi Sankyo DeepView → | HER2-positive unresectable and/or metastatic breast cancer | Phase 3 | Deep | View | |||
| DESTINY-PanTumor02 NCT04482309 · AstraZeneca DeepView → | HER2-expressing solid tumors | Phase 2 | Deep | View | |||
| TAPUR NCT02693535 · American Society of Clinical Oncology DeepView → | advanced solid tumors, non-Hodgkin lymphoma or multiple myeloma | Phase 2 | Deep | View | |||
| DESTINY-Lung04 NCT05048797 · AstraZeneca DeepView → | first-line HER2 exon 19/20-mutated advanced non-squamous NSCLC | Phase 3 | Deep | View | |||
| BEGONIA NCT03742102 · AstraZeneca DeepView → | first-line metastatic triple-negative breast cancer | Phase 1/Phase 2 | Deep | View | |||
| DESTINY-Gastric04 NCT04704934 · Daiichi Sankyo DeepView → | HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma | Phase 3 | Deep | View | |||
| DESTINY-Breast12 NCT04739761 · AstraZeneca DeepView → | previously treated advanced/metastatic HER2-positive breast cancer | Phase 3 | Deep | View | |||
| DESTINY-Lung02 NCT04644237 · Daiichi Sankyo DeepView → | HER2-mutant metastatic non-small-cell lung cancer | Phase 2 | Deep | View | |||
| DESTINY-Gastric01 NCT03329690 · Daiichi Sankyo Co., Ltd. DeepView → | HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma | Phase 2 | Deep | View | |||
| DESTINY-Breast01 NCT03248492 · Daiichi Sankyo DeepView → | HER2-positive metastatic breast cancer previously treated with T-DM1 | Phase 2 | Deep | View | |||
| DESTINY-CRC01 NCT03384940 · Daiichi Sankyo Co., Ltd. DeepView → | HER2-expressing metastatic colorectal cancer | Phase 2 | Deep | View | |||
| DESTINY-Gastric03 NCT04379596 · AstraZeneca DeepView → | advanced HER2-expressing gastric cancer | Phase 2 | Deep | View | |||
| DESTINY-Breast02 NCT03523585 · Daiichi Sankyo DeepView → | HER2-positive metastatic breast cancer previously treated with T-DM1 | Phase 3 | Deep | View | |||
| DESTINY-Gastric02 NCT04014075 · Daiichi Sankyo DeepView → | HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma | Phase 2 | Deep | View | |||
| TRADE-DXd NCT06533826 · Ana C Garrido-Castro, MD DeepView → | ADC-refractory HER2-negative metastatic breast cancer | Phase 2 | Deep | View | |||
| TUXEDO-1 NCT04752059 · Medical University of Vienna DeepView → | HER2-positive breast cancer with brain metastases | Phase 2 | Deep | View | |||
| DESTINY-Breast07 NCT04538742 · AstraZeneca DeepView → | HER2-positive metastatic breast cancer | Phase 1/Phase 2 | Deep | View | |||
| DESTINY-Breast08 NCT04556773 · AstraZeneca DeepView → | HER2-low metastatic breast cancer | Phase 1 | Deep | View | |||
| FORAGER-1 NCT05614739 · Eli Lilly and Company DeepView → | advanced solid tumors with FGFR3 alterations | Phase 1 | Deep | View | |||
| HER2CLIMB-04 NCT04539938 · Seagen, a wholly owned subsidiary of Pfizer DeepView → | previously treated HER2+ locally-advanced or metastatic breast cancer | Phase 2 | Deep | View | |||
| DEMETHER NCT06172127 · MedSIR DeepView → | HER2-positive unresectable locally recurrent or metastatic breast cancer | Phase 2 | Deep | View | |||
| DEBBRAH NCT04420598 · MedSIR StandardView → | HER2-positive/HER2-low breast cancer with central nervous system involvement | Phase 2 | Standard | View | |||
| TRUDI NCT05795101 · Filipa Lynce, MD StandardView → | stage III HER2-expressing inflammatory breast cancer | Phase 2 | Standard | View | |||
| DESTINY-Lung01 NCT03505710 · Daiichi Sankyo StandardView → | HER2-overexpressing or -mutated metastatic non-small cell lung cancer | Phase 2 | Standard | View | |||
| DESTINY-BTC01 NCT06467357 · AstraZeneca StandardView → | first-line HER2-expressing advanced biliary tract cancer | Phase 3 | Standard | View | |||
| SAPPHO NCT06439693 · Dana-Farber Cancer Institute StandardView → | de novo HER2+ metastatic breast cancer | Phase 2 | Standard | View | |||
| ARTEMIDE-Gastric01 NCT06764875 · AstraZeneca StandardView → | first-line HER2-positive gastric or gastroesophageal junction cancer | Phase 3 | Standard | View | |||
| SURVIVE HERoes NCT06643585 · Prof. Wolfgang Janni FocusedView → | Not given | Phase 3 | Focused | View | |||
| HERTHENA-Breast04 NCT07060807 · Merck Sharp & Dohme LLC FocusedView → | Not given | Phase 3 | Focused | View | |||
| MORPHEUS-panBC NCT03424005 · Hoffmann-La Roche FocusedView → | metastatic breast cancer | Phase 1/Phase 2 | Focused | View | |||
| DESTINY-CRC02 NCT04744831 · Daiichi Sankyo FocusedView → | HER2-positive advanced colorectal cancer | Phase 2 | Focused | View | |||
| HER2 PARADIGM NCT06750484 · Yale University FocusedView → | previously treated HER2-IHC 0 advanced breast cancer | Phase 2 | Focused | View | |||
| ERADICATE NCT07198724 · Kristina A. Fanucci FocusedView → | endocrine-resistant HR+/HER2-low or HER2-ultralow metastatic breast cancer | Phase 1/Phase 2 | Focused | View | |||